文献速递神经肿瘤

HyperArc 无框架直线加速器放射外科治疗良性颅内肿瘤的肿瘤控制与毒性分析

Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity.
PubMed 文献 · J Neurooncol · 2025-10-21

本研究回顾性分析了单中心2017至2021年使用 HyperArc 行立体定向放射外科治疗的198个良性颅内肿瘤靶点,处方剂量归一至≥99%的肿瘤总体积且不做计划靶体积外扩。中位随访2.6年,10.1%肿瘤进展,多数为复发 WHO II 级脑膜瘤;3级及以上中枢神经系统毒性发生率为4.3%,听力和视力保留率分别为98.9%和99.5%。

要点

  • HyperArc 无外扩计划可高效治疗多种良性颅内肿瘤,计划质量高、剂量跌落陡峭。
  • 肿瘤进展率10.1%,主要见于复发 WHO II 级脑膜瘤。
  • 3级及以上中枢神经系统毒性4.3%,听力和视力保留率分别为98.9%和99.5%。

核心结论

  • 不做计划靶体积外扩时,HyperArc 能为多种良性颅内肿瘤高效提供高质量、剂量跌落陡峭的计划。
  • 早期临床结局和毒性与历史对照一致。

研究设计与样本

  • 单中心回顾性研究,纳入2017至2021年接受 HyperArc 立体定向放射外科治疗的良性颅内肿瘤患者。
  • 共治疗198个良性颅内肿瘤靶点,靶点体积最小0.1 cc、最大58.9 cc。
  • 处方剂量归一至≥99%的肿瘤总体积,不做额外外扩。
  • 治疗在 Varian Edge 直线加速器上实施,使用10MV 无均整器束流、最高2400 MU/min 和高清晰度多叶准直器。

主要发现

  • 共治疗8种良性颅内肿瘤,最常见为脑膜瘤130个、垂体腺瘤30个、听神经鞘瘤23个。
  • 45.1%靶点接受单次12-22 Gy 治疗,54.9%接受分次立体定向放射外科24-35 Gy 治疗。
  • 平均 RTOG 适形指数为1.12,平均 Paddick 梯度指数为3.31。
  • 74%靶点采用3弧治疗,平均治疗时间10.5分钟,平均随访2.6年。
  • 198个肿瘤中20个(10.1%)进展,平均失败时间2.1年;进展者中19个为脑膜瘤,17个为既往手术后的 WHO 2级。

关键数值与推荐

  • 处方剂量归一至≥99%的肿瘤总体积,不做计划靶体积外扩。
  • 单次剂量12-22 Gy 或分次立体定向放射外科24-35 Gy。
  • 平均 RTOG 适形指数1.12,平均 Paddick 梯度指数3.31。

临床怎么用

  • HyperArc 可用于多种良性颅内肿瘤的无框架立体定向放射外科治疗,计划质量高且治疗时间较短。
  • 对复发 WHO II 级脑膜瘤应加强随访,因其占进展病例的多数。

局限性

  • 单中心回顾性设计,平均随访2.6年。
  • 未设对照组,早期结局仅与历史对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: HyperArc™ (HA) automates both planning and delivery of single-isocenter VMAT radiosurgery (SRS) and was designed for complex multi-metastasis cases. The clinical effectiveness of treating benign intracranial tumors (BIT) with HA is unknown. We collected data on treatment planning, delivery, and clinical outcomes of BIT managed with SRS since HA deployment. METHODS: Patients received SRS using HA from 2017 to 2021 at a single institution. Prescription dose was normalized to ≥ 99% of gross tumor volume without additional expansion. Treatments were delivered on Varian Edge linear accelerator with 10MV flattening-filter free beam at up to 2400 MU/min with high-definition multi-leaf collimator. Post-treatment imaging, toxicities, and outcomes were assessed. RESULTS: 198 BIT targets (min = 0.1 cc, max = 58.9 cc) were treated. A large variety (n = 8) of BIT were treated with the most common pathologies being meningiomas (130), pituitary adenomas (30), and acoustic schwannomas (23). Nearly half (45.1%) were treated in a single fraction (12-22 Gy) versus 54.9% with fractionated SRS (24-35 Gy). Mean RTOG CI and Paddick GI were 1.12 and 3.31, respectively. A majority (74%) were treated with 3 arcs with mean treatments lasting 10.5 min. Mean FU was 2.6 years. 20 of 198 (10.1%) tumors progressed with mean time to failure being 2.1 years. Tumor progression occurred in 10.1%, mostly in recurent WHO II meningiomas. Of those that progressed, 19 were meningiomas with 17 being WHO grade 2 with prior surgery. Grade 3 + CNS toxicity was reported in 4.3% of patients, with 98.9 and 99.5% hearing and visual preservation, respectively. CONCLUSIONS: Without any planning target volume expansion, HA efficiently delivers high-quality plans with sharp dose fall-off for a wide variety of BITs. Early clinical outcomes and toxicity are consistent with historical controls.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hotsinpiller WS, Thomas EM, Tsekouras I, et al. Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity. J Neurooncol. 2025. PMID: 41118008. doi:10.1007/s11060-025-05291-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。